Androgen receptor pathway inhibitor (ARPI) monotherapy increases gynecomastia and breast pain in prostate cancer patients compared with androgen deprivation therapy (ADT), while ARPI plus ADT does not significantly differ from ADT alone. Here, AR is linked to prostate cancer.